RIO DE JANEIRO, BRAZIL - In recent weeks, some of the most promising vaccines under development against Covid-19 have released their preliminary clinical trials results on efficacy and safety. Four of the 11 vaccines in Phase 3 trials on a global scale, the last step before filing for registration, have already provided satisfactory safety and efficacy data on protection against the disease.
Although the federal government has only signed a contract with AstraZeneca, recent news suggest . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here